Mediwelcome Healthcare Management & Technology Inc. provided unaudited consolidated earnings guidance for the six months ended June 30, 2021. For the six months, the Group is expected to record an increase in the net loss of approximately 310% comparing with the corresponding period last year whereas the unaudited consolidated net loss recorded in the corresponding period last year was approximately RMB 4.0 million. In the opinion of the Board, the increase in the net loss was primarily attributable to (i) the increase in listing expenses when compared with the corresponding period last year since the Group listed in 2021, which is approximately RMB 11.3 million for the Period as compared with approximately RMB 3.5 million for the six months ended 30 June 2020; and (ii) the grant of a total of 15,170,000 restricted share units to 31 eligible participants under the restricted share units scheme by the Group on 25 June 2021 in recognition of their contributions to the development of the Group and to incentivise them to further promote the development of the company, which was recognized as share-based compensation expenses of approximately RMB 9 million for the Period. The Group did not record any share-based compensation expenses during the corresponding period in 2020.